Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Illumina’s record EU fine could drive smaller M&A pharma deals

By Brian Buntz | July 5, 2023

This table summarizes some of the largest fines imposed by the European Union on companies for various violations

This table summarizes some of the largest fines from the European Union on companies for a variety of violations.

Illumina, the world’s largest gene sequencing company, faces a record fine from the E.U. for acquiring startup Grail without approval. The $8 billion deal closed in August 2021 despite ongoing EU. and U.S. investigations. A year later, the EU prohibited the merger, citing reduced innovation and choice. The expected $453 million fine, which would be the largest ever in the E.U. that aims to deter unauthorized deals. The chart on the right shows some of the most substantial fines in EU history.

Francis deSouza resigned as CEO and director of Illumina Inc. on June 11, 2023. The company named Charles Dadswell, senior vice president and general counsel, as interim CEO, while the board conducts a search for a new CEO.

Grail’s pioneering work on early cancer detection through blood tests puts it at the forefront of oncological research. But Illumina’s attempt to acquire the firm is now a cautionary tale for the life sciences, as FT reported.

The Illumina-Grail controversy could put pressure on M&A deal size

The substantial penalties that Illumina faces may catalyze the recent shift in pharma M&A, nudging companies toward smaller and more strategic deal sizes. Already, the total valuation of M&A deals in the pharma sector has dipped, now registering in the single-digit billions in May and June. The valuation of M&A deals peaked in March with Pfizer’s purchase of Seagen for $43 billion, bringing total activity to close to $46 billion.

Pharma M&A activities in Q2 2023 indicated a downward trend in deal sizes, signifying a possible shift in acquisition strategies. Notable acquisitions, such as Lilly’s acquisition of Sigilon and DICE Therapeutics, and Shionogi’s acquisition of Qpex Biopharma, exemplify the move towards smaller, strategic deals.

FTC increasing enforcement activity in life sciences

In 2023, there has been an increase in U.S. case law and pharmaceutical antitrust pressure. This includes antitrust claims under the rule of reason test the U.S. Supreme Court announced in FTC v. Actavis for innovator and generic settlements of pharmaceutical patent litigation involving alleged reverse payments or ‘pay-for-delay’; innovator pharmaceutical companies face product-hopping antitrust claims that introduce new versions of brand-name drugs facing generic competition; and legislators, regulators and courts drive pharmaceutical pricing developments involving legislation, regulations and legal challenges.

In April, FTC concluded that Illumina’s Grail acquisition was “likely to substantially reduce competition” in the U.S.

Recent enforcement activity indicates the FTC is prepared to move from rhetoric to action in the life sciences space, at least for the very largest transactions. The agency had previously cleared all life sciences transactions involving therapeutics (with the notable exception of consolidations in generics), but on May 16, 2023, the FTC announced that it had filed a lawsuit to block the Amgen/Horizon transaction. There is also increasing scrutiny on pharmacy benefit managers (PBMs).


Filed Under: Biologics, Genomics/Proteomics, Legal precedents and interpretations
Tagged With: biotech acquisitions, EU antitrust, Grail, Illumina, Industry Trends, pharma regulations, pharmaceutical M&A
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
A media release and Scientific Report image of Elizabeth Kellogg. - Camera Settings: ILCE-9M2, 12mm, ISO 1000, 1/80, f/3.2, Fri, 04-19-2024 at 10:10. v.12.01.23
St. Jude pioneers gene editing and structural biology to advance pediatric research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE